Metastatic Solid Tumors: Clinical Trials

59 trials for Metastatic Solid Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 16 recruiting, 7 not yet recruiting, 7 terminated. 59 Phase 1, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 159Completed 20, Recruiting 16, Not yet recruiting 7, Terminated 7, Active not recruiting 4, Unknown 2, Withdrawn 2, Suspended 1
Phase 215Recruiting 6, Not yet recruiting 4, Terminated 2, Withdrawn 2, Completed 1

Follow Metastatic Solid Tumors: new trials by email Literature Review of Metastatic Solid Tumors trials Research Report on Metastatic Solid Tumors

Trials (filtered) newest first · largest first

All 59 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
MC001 - Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer
Phase 1Not yet recruitingMedicovestor, Inc402026-12-012026-11-03
A Study of IOV-5001 in Adults With Advanced Solid Tumors
IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingIovance Biotherapeutics, Inc.1062026-09-012026-09-15
SLR-108 PET Imaging in Subjects With Advanced Cancer
SLR-108, SLX-1411 - Metastatic Solid Tumors
Phase 1RecruitingSolve Therapeutics702026-08-042026-11-17
Study of QLS5308 in Patients With Advanced Solid Tumors
QLS5308 IV infusion - Metastatic Solid Tumors
Phase 1Not yet recruitingQilu Pharmaceutical Co., Ltd.1922026-03-282026-03-10
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
EB-NK-301, Fludarabine - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1 / Phase 2RecruitingBeijing Biotech602026-03-022026-05-15
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
ADCX-020 - Advanced Malignancy, Advanced Solid Cancers
Phase 1RecruitingAdcytherix SAS2902026-02-232026-06-08
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1 / Phase 2RecruitingRevolution Medicines, Inc.3702026-01-302026-11-04
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
BL-B01D1, VSV injection, CVL006 - Rare Malignant Neoplasm, Advanced Solid Tumors
Phase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences6002026-01-012025-12-29
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion - Metastatic Solid Tumors
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.2902025-12-302025-12-09
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
BPR-6023021 for injection - Metastatic Solid Tumors
Phase 1 / Phase 2Not yet recruitingChengdu Syncor Pharmaceutical Co., Ltd.1952025-11-192025-11-25
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
CKD-512, Pembrolizumab - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1RecruitingChong Kun Dang Pharmaceutical602025-10-162026-02-02
A Study of DS3610a in Participants With Advanced Solid Tumor
DS3610a - Solid Tumors, Metastatic Solid Tumors
Phase 1RecruitingDaiichi Sankyo702025-10-092026-11-12
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced
Phase 1 / Phase 2RecruitingAvenzo Therapeutics, Inc.3552025-10-022026-10-05
SLV-324 Treatment of Metastatic Solid Tumors
SLV-324 intravenous (IV infusion) - Metastatic Solid Tumors
Phase 1RecruitingSolve Therapeutics702025-08-252026-02-23
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
SKB107 for injection - Metastatic Solid Tumors
Phase 1RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.902025-08-152026-05-08
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
ERAS-4001, ERAS-4001 in combination - Metastatic Solid Tumors
Phase 1RecruitingErasca, Inc.2002025-08-062025-12-03
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
INCB177054, Retifanlimab - Solid Tumors, Advanced Solid Tumors
Phase 1 / Phase 2TerminatedIncyte Corporation92025-06-302026-09-02
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
ERAS-0015, ERAS-0015 in combination - Metastatic Solid Tumors
Phase 1RecruitingErasca, Inc.6002025-06-052026-11-16
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced
Phase 1 / Phase 2RecruitingAvenzo Therapeutics, Inc.4802025-06-042026-10-16
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
ODC-IL2 - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1RecruitingTrutino Biosciences Inc.502024-12-302025-01-13

Showing 20 of 59. Sign in to see all of them.

Narrower conditions

Neoplasm Metastasis (13)  ·  Neoplasms (12)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Colorectal Neoplasms (4)  ·  Lung Neoplasms (4)  ·  Pancreatic Neoplasms (3)  ·  Sarcoma (3)  ·  Stomach Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Carcinoma (2)  ·  Head and Neck Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Acrocephalosyndactylia (1)  ·  Adenocarcinoma (1)

Broader conditions

Neoplasms (15)  ·  Neoplastic Processes (13)  ·  Pathologic Processes (13)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Neoplasms by Site (12)  ·  Digestive System Diseases (11)  ·  Digestive System Neoplasms (10)  ·  Bronchial Neoplasms (8)  ·  Carcinoma, Bronchogenic (8)  ·  Lung Diseases (8)  ·  Respiratory Tract Diseases (8)  ·  Respiratory Tract Neoplasms (8)  ·  Thoracic Neoplasms (8)  ·  Gastrointestinal Diseases (7)  ·  Gastrointestinal Neoplasms (7)

Interventions

pembrolizumab (5)  ·  Carboplatin (3)  ·  Cetuximab (3)  ·  Gemcitabine (3)  ·  130-nm albumin-bound paclitaxel (2)  ·  Albumin-Bound Paclitaxel (2)  ·  Infusions, Intravenous (2)  ·  Injections (2)  ·  Panitumumab (2)  ·  atezolizumab (2)  ·  repotrectinib (2)  ·  (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1)  ·  Alpelisib (1)  ·  BMS 181339 (1)  ·  BMS 754807 (1)

Sponsors

Incyte Corporation (3)  ·  Turning Point Therapeutics, Inc. (3)  ·  Avenzo Therapeutics, Inc. (2)  ·  EMD Serono Research & Development Institute, Inc. (2)  ·  Erasca, Inc. (2)  ·  Genentech, Inc. (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Qilu Pharmaceutical Co., Ltd. (2)  ·  Solve Therapeutics (2)  ·  AbbVie (1)  ·  Adcytherix SAS (1)  ·  Alphamab (Australia) Co Pty Ltd. (1)  ·  Astex Pharmaceuticals, Inc. (1)  ·  BeOne Medicines (1)  ·  Beijing Biotech (1)

Countries

United States (38)  ·  China (12)  ·  Spain (12)  ·  Australia (11)  ·  Canada (11)  ·  South Korea (10)  ·  France (8)  ·  United Kingdom (7)  ·  Italy (6)  ·  Belgium (4)  ·  Japan (4)  ·  Singapore (4)  ·  Taiwan (4)  ·  Denmark (3)  ·  Germany (3)

Top investigators

Gerri Lee (2)  ·  Alexander JB McEwan, MB,FRCPC (1)  ·  Apostolia Tsimberidou, MD, PHD (1)  ·  Arlene Chan (1)  ·  Dan Levitt, M.D. (1)  ·  Eiji Ueda, MD, PhD, MBA (1)  ·  Ivan Gergel, MD (1)

Results publications

PMID 22025163, PMID 25239610, PMID 26565381, PMID 26884591, PMID 30093503, PMID 31838007, PMID 31838015, PMID 32269053, PMID 32508818, PMID 33646820, PMID 34427452, PMID 34814185, PMID 35338084, PMID 35354274, PMID 36394153, PMID 38197815, PMID 39509670, PMID 39549678, PMID 39929671, PMID 40341199, PMID 41639379, PMID 41724817

NIH funding

2023 (2), 2025 (2), 2017 (1), 2019 (1)